Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis

Main measures

• is to test the hypothesis that subjects with relapsing remitting-multiple sclerosis (RRMS) in at least one LY2127399 group will have statistically significantly fewer cumulative total gadolinium (Gd)-enhancing MRI lesions over Weeks 12, 16, 20, and 24 compared to subjects in the placebo group.

  MRI lesions

• Addition of Belimumab to B-cell Depletion in Relapsing-re…

  Phase 2 · Stopped early

  Stopped early

• A Study of Participants With Relapsing-Remitting Multiple…

  Phase 2 · Completed

  Results posted, no main test reported

• ATAMS ext

  Phase 2 · Stopped early

  Stopped early

• Atacicept 28063 (RMS) extension study

  Phase 2 · Completed

  No result found

• ATAMS

  Phase 2 · Stopped early

  Stopped early

• Atacicept frequent MRI study in RMS

  Phase 2 · Ongoing

  Still running

1. 2026-10-28In scope changed from true to false

1. Started

   Dec 2008